S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML

Journal article

Open access

Peer reviewed

HemaSphere, Vol.6, pp.1-2

2022-06-01

Files and links (1)

url

https://doi.org/10.1097/01.hs9.0000843296.73803.85View

Published (Version of record) Open

4 Record Views

Title: S100: QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML
Creators: Mikkael Sekeres - Miller School of Medicine
Publication Details: HemaSphere, Vol.6, pp.1-2
Publisher: Wolters Kluwer
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031757780302976